- Trial Phase
- Filed/PDUFA (BLA under FDA review); also multiple ongoing Phase 3 trials
- Time to Market
- If approved, potential US launch in late 2026 or early 2027. Already approved in China (May 2024).
- Why 8/10
- The next hard catalyst is the FDA PDUFA decision date of November 14, 2026, for the BLA seeking approval of ivonescimab + chemotherapy in EGFR-mutated NSCLC after TKI therapy. As Summit's sole clinical-stage asset, this is a make-or-break binary within roughly 4.5 months, justifying an impactScore of 8.
The November 14 PDUFA is the defining event. The HARMONi global trial showed statistically significant PFS but OS missed the pre-specified threshold — an unusual situation that creates binary risk on approval odds. Watch for an FDA Advisory Committee date (if scheduled) as a pre-decision signal. Also watch HARMONi-3 final PFS readout (2H 2026) as a secondary catalyst. The $500M June offering diluted existing holders but extended the cash runway, and the massive insider buying (~$100M from co-CEOs at ~$13.12) signals conviction at current levels.
Price Chart
Executive Summary
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody and Summit Therapeutics' sole clinical-stage asset, licensed from Chinese biotech Akeso. Already approved in China, its BLA for EGFR-mutated NSCLC is under FDA review with a PDUFA decision by November 14, 2026 — a high-stakes binary for a single-asset company. The drug has generated mixed clinical data: strong PFS results across multiple trials, but overall survival (OS) missed pre-specified thresholds in both the global HARMONi trial and the HARMONi-2 head-to-head vs Keytruda. However, the HARMONi-6 trial demonstrated a positive OS signal (34% risk reduction) presented at ASCO 2026. After a volatile 2026 — interim PFS miss, $500M dilutive offering, and insider buying of ~$100M — the stock trades near its 52-week low with a mean analyst target implying ~46% upside.
How It Works
Ivonescimab is a "bispecific" antibody — a single engineered protein that simultaneously blocks two different cancer-support pathways: PD-1 (which tumors use to turn off the immune system's T-cells) and VEGF (which tumors use to grow new blood vessels to feed themselves). Blocking both pathways together is designed to be more effective than blocking either one alone.
Trial Status
The BLA is under FDA review with a PDUFA date of November 14, 2026, based on the global Phase 3 HARMONi trial in EGFR-mutated NSCLC after TKI failure. That trial met its PFS primary endpoint but OS did not reach the pre-specified statistical threshold — though the company argues the trend supports approval. The HARMONi-6 trial (China, squamous NSCLC) showed a statistically significant OS benefit (HR=0.66) vs tislelizumab, presented at the ASCO 2026 plenary. The HARMONi-3 global trial (1L NSCLC vs Keytruda+chemo) had an interim PFS analysis miss the early statistical bar (the company said it was set unusually high) but enrollment continues. A Phase 2 colorectal cancer trial showed encouraging early data (ORR 70.8%, DCR 100%).
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision date November 14, 2026 for ivonescimab + chemo in EGFR-mutated NSCLC
- Potential FDA Advisory Committee meeting (date TBD) ahead of the PDUFA
- HARMONi-3 final PFS readout expected in second half of 2026
- HARMONi-3 non-squamous cohort enrollment completion and interim data
- HARMONi-GI3 Phase 3 colorectal cancer trial data (early stage)
Source Filing
The SEC filing that triggered this drug report: